Could Increasing, Not Decreasing, Amyloid-Beta 42 Slow Alzheimer’s?
A groundbreaking study published in the prestigious journal Brain challenges the long-held belief that Alzheimer’s disease treatment focuses solely on reducing amyloid plaques. Researchers at the University of Cincinnati discovered that monoclonal antibody drugs, designed to target amyloid plaques, may actually slow cognitive decline by boosting levels of a critical brain protein called amyloid-beta 42 (Aβ42).
Understanding Amyloid-Beta 42: Friend or Foe?
Amyloid-beta is a protein fragment naturally produced in the brain. While several forms exist, Aβ42 has been implicated in Alzheimer’s disease. While more common forms, like Aβ40, are relatively benign, Aβ42 is prone to clumping, forming amyloid plaques. These plaques were long considered the primary culprit behind Alzheimer’s symptoms.
The amyloid cascade hypothesis, dominant for decades, posits that Aβ42 clumps trigger inflammation and neuronal damage, leading to Alzheimer’s. However, despite numerous clinical trials targeting amyloid plaques, the results have been largely disappointing. Many trials showed minimal cognitive benefits, and some even worsened symptoms.
A Shift in Perspective: Proteinopenia Hypothesis
Professor Alberto J. Espay, director of the Gardner Family Center for Parkinson’s Disease and Movement Disorders, and his team propose a new perspective: the proteinopenia hypothesis. This theory suggests that Alzheimer’s isn’t solely caused by amyloid plaque buildup, but rather by the depletion of soluble Aβ42.
“Most anti-Aβ interventions had succeeded in clearing the brain from amyloid plaques, yet they were either futile or statistically favored the placebo group,” explains Professor Espay. “I was interested in finding out what made aducanumab, lecanemab, and donanemab special. Along the way, I learned that along with removing amyloid, virtually all monoclonal anti-Aβ antibodies also increase Aβ42 in cerebrospinal fluid.”
Boosting Aβ42: A Potential Breakthrough?
Their recent study analyzed data from 24 clinical trials involving nearly 26,000 patients with early or moderate Alzheimer’s. The researchers focused on changes in amyloid plaque levels, cerebrospinal fluid levels of Aβ42, and cognitive performance. Their findings revealed a strong correlation between increases in Aβ42 levels and improved cognitive outcomes. Conversely, treatments lowering Aβ42 levels worsened cognitive performance.
These results suggest that amyloid plaques may not be the primary driver of Alzheimer’s symptoms. Instead, they might represent a protective response. The real issue, according to Professor Espay, could be the depletion of soluble Aβ42, essential for neuron health and synaptic function.
Looking Ahead: Towards Targeted Therapies
While promising, this research has limitations. Analyzing aggregated data from clinical trials limits precision, and individual patient responses may vary. Further research is needed to confirm these findings and explore safer ways to boost Aβ42 levels.
“There is resistance to looking at Alzheimer’s as a loss, which is paradoxical,” Professor Espay notes. “We have long become too comfortable with the idea that Alzheimer’s is about a ‘gain’—of the amyloid plaques. But in fact, amyloid forms as a reaction to many things. And if too much of it is necessary in such a reaction, less of the normal protein from which it comes (Aβ42) remains.”
A Call to Action: Support Alzheimer’s Research
This groundbreaking research offers a new hope in the fight against Alzheimer’s disease. Understanding the role of Aβ42 opens doors for innovative therapies that target the root cause of cognitive decline. Support Alzheimer’s research and contribute to finding effective treatments for this devastating disease.